CNSP CNS Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-10 16:00
Why CNSP matters now
CNS Pharmaceuticals, Inc. (CNSP) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.17 with -2.91% on the session and $3.0M in market capitalization; recent performance reads 1-month -1.67% and YTD -10.48%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-4.9M, and EPS of $-7.30. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -564.4%.
The latest indexable market news headline is "CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment" from Accesswire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $0.50; recent insider activity includes Charles Faith L. filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
44.95
P/S
0.00
EV/EBITDA
0.00
DCF Value
$7.66
FCF Yield
-564.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-238.7%
ROA
-354.3%
ROIC
-5485.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-4.9M | $-7.30 |
| Q4 2025 | $0.00 | $-6.0M | $-10.15 |
| FY 2025 | $0.00 | $-15.9M | $-35.75 |
| Q3 2025 | $0.00 | $-3.2M | $-5.76 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$0.50
Target (Median)
$0.50
Target Range
$0.50 - $0.50
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.03
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.